ONBILTO

Serial Number 98959530
688

Registration Progress

Application Filed
Jan 14, 2025
Under Examination
Dec 2, 2025
Approved for Publication
Oct 7, 2025
Published for Opposition
Oct 7, 2025
Registered

Attorney Assistance

NOA E-Mailed - SOU Required
Due: Jun 02, 2026 141 days

Trademark Image

ONBILTO

Basic Information

Serial Number
98959530
Filing Date
January 14, 2025
Published for Opposition
October 7, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
688
Status Date
Dec 2, 2025
Application
Pending
Classes
005

Rights Holder

Dr. Reddy's Laboratories SA

99
Address
Elisabethenanlage 11
Basel 4051
CH

Ownership History

Dr. Reddy's Laboratories SA

Original Applicant
99
Basel CH

Dr. Reddy's Laboratories SA

Owner at Publication
99
Basel CH

Legal Representation

Attorney
Michael S. Hargis

USPTO Deadlines

Next Deadline
141 days remaining
NOA E-Mailed - SOU Required
Due Date
June 02, 2026
Extension Available
Until December 02, 2026

Application History

14 events
Date Code Type Description Documents
Dec 2, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Oct 7, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Oct 7, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Oct 1, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Sep 10, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Sep 9, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Sep 9, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Sep 9, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jun 24, 2025 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jun 24, 2025 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jun 24, 2025 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jun 23, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Jan 14, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jan 14, 2025 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical and medicinal preparations for the treatment of osteoporosis in postmenopausal women and for the treatment and prevention of bone loss in adults at increased risk of fracture

Classification

International Classes
005